Atlas Capital Advisors Inc. Takes Position in Labcorp Holdings Inc. $LH

Atlas Capital Advisors Inc. bought a new stake in Labcorp Holdings Inc. (NYSE:LH) in the fourth quarter, HoldingsChannel reports. The fund bought 3,840 shares of the medical research company’s stock, valued at approximately $963,000.

Other large investors have also modified their holdings of the company. Aptus Capital Advisors LLC grew its stake in Labcorp by 7.3% during the 4th quarter. Aptus Capital Advisors LLC now owns 2,183 shares of the medical research company’s stock valued at $548,000 after purchasing an additional 149 shares in the last quarter. Alamea Verwaltungs GmbH acquired a new stake in Labcorp during the 4th quarter valued at approximately $730,000. Prosight Management LP acquired a new stake in Labcorp during the 4th quarter valued at approximately $8,663,000. Kestra Advisory Services LLC grew its stake in Labcorp by 9.8% during the 4th quarter. Kestra Advisory Services LLC now owns 14,048 shares of the medical research company’s stock valued at $3,524,000 after purchasing an additional 1,258 shares in the last quarter. Finally, Maverick Capital Ltd. grew its stake in Labcorp by 73.1% during the 4th quarter. Maverick Capital Ltd. now owns 17,564 shares of the medical research company’s stock valued at $4,406,000 after purchasing an additional 7,415 shares in the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Labcorp Trading Down 0.3%

Shares of NYSE LH opened at $265.45 on Monday. The company has a market cap of $21.77 billion, a price-to-earnings ratio of 23.51, a price-to-earnings-growth ratio of 1.86 and a beta of 0.90. Labcorp Holdings Inc. has a 12-month low of $241.81 and a 12-month high of $293.72. The company has a current ratio of 1.73, a quick ratio of 1.54 and a debt-to-equity ratio of 0.68. The stock’s 50 day simple moving average is $262.65 and its 200 day simple moving average is $265.78.

Labcorp (NYSE:LH) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.09 by $0.16. The business had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.51 billion. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The business’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the business posted $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Equities research analysts expect that Labcorp Holdings Inc. will post 18 EPS for the current year.

Labcorp Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, June 11th. Investors of record on Friday, May 29th were issued a $0.72 dividend. The ex-dividend date of this dividend was Friday, May 29th. This represents a $2.88 annualized dividend and a dividend yield of 1.1%. Labcorp’s dividend payout ratio (DPR) is 25.51%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Piper Sandler raised their price objective on Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a research note on Tuesday, February 24th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Labcorp in a research report on Friday, May 8th. Robert W. Baird set a $334.00 target price on Labcorp in a research report on Friday, May 1st. Evercore reiterated an “outperform” rating and issued a $300.00 target price on shares of Labcorp in a research report on Wednesday, April 8th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Labcorp in a research report on Tuesday, February 17th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Labcorp currently has a consensus rating of “Moderate Buy” and an average price target of $308.00.

Insider Activity at Labcorp

In related news, CEO Adam H. Schechter sold 5,903 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $254.50, for a total value of $1,502,313.50. Following the sale, the chief executive officer owned 107,234 shares of the company’s stock, valued at approximately $27,291,053. This trade represents a 5.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Kathryn W. Kyle sold 762 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $263.89, for a total value of $201,084.18. Following the completion of the sale, the executive vice president directly owned 3,813 shares in the company, valued at approximately $1,006,212.57. This trade represents a 16.66% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.84% of the company’s stock.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.